加载中
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
前收盘价
US$2.53
−US$0.05 · -1.94%
盘中时间采用ET。市场数据可能有所延迟。
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
日内区间
当前US$2.53
52周区间
当前US$2.53
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
33
偏贵
情绪
53
多空交织
风险
45
风险偏高
动量
63
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
日内区间
当前US$2.53
52周区间
当前US$2.53
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 125.1万 USD | 108.6万 USD | — | — | — |
| 毛利 | −125.1万 USD | −108.6万 USD | — | — | — |
| 研究与开发 | 4484.5万 USD | 5526.7万 USD | 4263.7万 USD | 3715.9万 USD | 1927.8万 USD |
| 销售、一般及管理费用 | 1870.7万 USD | 1800万 USD | 1215.9万 USD | 931万 USD | 602.3万 USD |
| 营业费用 | 6230.1万 USD | 7218.1万 USD | 5479.6万 USD | 4646.9万 USD | 2530.1万 USD |
| 利息收入 | 535.7万 USD | 789.2万 USD | 528.2万 USD | 66.8万 USD | 9.6万 USD |
| 折旧和摊销 | 125.1万 USD | 108.6万 USD | 95.7万 USD | 94.2万 USD | 68.2万 USD |
| 营业利润 | −6355.2万 USD | −7326.7万 USD | −5479.6万 USD | −4646.9万 USD | −2530.1万 USD |
| 净利润 | −5819.7万 USD | −6536.3万 USD | −4943.4万 USD | −4590.1万 USD | −2521万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
